Drug Trial Radar · NCT01697722
Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy
Last checked: Nov 19, 2026Latest source record: Oct 4, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
815,377
Actual
Start
Jan 1991
Primary completion
Jun 2007
Study completion Feb 2010
Sponsor
- Lead sponsor
- Research in Real-Life LtdResearch network
- Sponsor type
- Research network
- Collaborators
- Teva Branded Pharmaceutical Products R&D, Inc.
- First posted
- Oct 2, 2012
Design
- Study type
- Observational
- Who can join
- All sexes, from 5 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the effectiveness, cost-effectiveness and direct healthcare costs of asthma management in patients with evidence of persistent asthma following an increase in asthma therapy in the form of either an increased dose of inhaled glucocorticosteroids (ICS) using extrafine hydrofluoroalkane-beclometasone dipropionate (HFA-BDP) via pressurised metered-dose inhaler (pMDI) or breath-actuated inhaler (BAI), or a change to combination ICS plus long-acting bronchodilator (LABA) therapy using fixed combinations (fluticasone propionate / salmeterol \[FP/SAL\] or budesonide / formoterol \[BUD/FOR\]) or separate pMDIs and BAIs.
Conditions
- Asthma
Interventions
Extra-fine hydrofluoroalkane-beclometasone dipropionateDrug
Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI
ICS / LABA via separate pMDI and / or BAI inhalersDrug
A step-up from baseline ICS therapy via the addition of a separate long-acting beta-agonist with no change in baseline ICS drug or dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proxy asthma controlTime frame: One-year outcome period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
General Practice Research Database
London, London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.